GVB Biopharma has commenced an international growth strategy that will include direct investment in joint ventures and marketing/distribution agreements with partners in the United Kingdom, Europe and Asia-Pacific.
Find out if we can ship to you.
We can't ship to this country.
We can ship to this country.
300 Outdoor Acres & 33,000 sq ft Manufacturing Facility
Capabilities: Cultivation, Extraction, Bulk Raw maperial Manufacturing & Distribution
Sales & Administration Office
Corporate Headquarters & 40,000 sqft Facility
Capabilities: Private / White Label Product Manufacturing
Sales Office
Sales Office
Sales & Distribution Center
Sales Office & Distribution Center
Sourcing Office
The information provided is for informational purposes only and should not be relied upon. Parties should seek local counsel to ensure compliance with all regulations. GVB makes no representation as to the accuracy of the information provided and disclaims all liability for any party's reliance on the information provided.
GVB recognizes that the cannabinoid market in the UK is rapidly fragmenting from the EU common market and requires consideration as a unique and singular market. To better serve the UK market, GVB has opened a sales and distribution facility in the UK led by experts who have unique relationships with incumbent players in the nutraceutical market.
To further support increased access to European markets, GVB has opened a sales office and distribution facility in Brussels, Beligum. Brussels provides direct access to the European Single Market as well as efficient national regulations that make it an ideal hub for GVB's European operations.
GVB operates a sourcing office in Xiamen in Fujian Provence, China. This office will manage GVB's East Asian supply chains, ensuring GVB has direct access to suppliers throughout the region. By operating locally in China, GVB expects reduced costs, increased quality, and to build longterm relationships with suppliers.